AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reissued by equities researchers at Goldman Sachs Group, Inc. (The) in a report issued on Tuesday. They currently have a GBX 3,800 ($50.49) price target on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price objective would suggest a potential downside of 26.58% from the company’s previous close.

A number of other brokerages have also recently commented on AZN. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Deutsche Bank AG dropped their price target on AstraZeneca plc from GBX 5,700 ($75.74) to GBX 5,300 ($70.42) and set a “buy” rating on the stock in a research report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($54.48) price target on AstraZeneca plc and gave the stock a “sell” rating in a research report on Tuesday, August 8th. Sanford C. Bernstein set a GBX 5,780 ($76.80) price target on AstraZeneca plc and gave the stock a “buy” rating in a research report on Monday, September 25th. Finally, Credit Suisse Group reissued a “neutral” rating and issued a GBX 5,000 ($66.44) price target on shares of AstraZeneca plc in a research report on Monday, June 19th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON AZN) opened at 5176.00 on Tuesday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 4,885.88 and a 200-day moving average price of GBX 4,910.79. The company’s market cap is GBX 65.53 billion.

WARNING: “Goldman Sachs Group, Inc. (The) Reiterates “Sell” Rating for AstraZeneca plc (AZN)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/goldman-sachs-group-inc-the-reiterates-sell-rating-for-astrazeneca-plc-azn/1639897.html.

In related news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.